Drugs / Targovax TG01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06015724 | Jan 2024 → Jun 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Georgetown University | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-02-06 | Targovax Oy | Targovax TG01 immunotherapy reaches phase IIA in operable pancreatic cancer circio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Targovax TG-01 | “KRAS vaccine (Targovax TG-01/Stimulon QS-21)” NCT06015724 ↗1“Stimulon QS-21 and Targovax TG01” NCT06015724 ↗ |
| Modality | Vaccine | “KRAS vaccine” NCT06015724 ↗ |